Ligand Pharmaceuticals Incorporated (LGND)
| Previous close | 72.32 |
| Open | 73.53 |
| Bid | 72.48 x 200 |
| Ask | 73.49 x 100 |
| Day's range | 72.57 - 73.92 |
| 52-week range | 49.24 - 94.57 |
| Volume | |
| Avg. volume | 179,366 |
| Market cap | 1.309B |
| Beta (5Y monthly) | 0.92 |
| PE ratio (TTM) | 24.05 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 02 Jul 2010 |
| 1y target est | N/A |
- Business Wire
Ligand to Report First Quarter 2024 Financial Results on May 7, 2024
JUPITER, Fla., April 23, 2024--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report first quarter 2024 financial results after the close of the U.S. financial markets on Tuesday, May 7, 2024, and will hold a conference call at 4:30 p.m. Eastern Time that same day to discuss financial results and provide a general business update.
- Business Wire
Ligand Pharmaceuticals Announces New Topiramate Injection Data Presented at 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference
LONDON, April 08, 2024--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its partners at the University of Minnesota (UMN) and CURx Pharmaceuticals, Inc. presented new data on Captisol-enabled™ Topiramate Injection (IV topiramate), a potential replacement therapy for the treatment of certain emergent neurological conditions, including epilepsy, when oral administration is not feasible.
- Business Wire
Ligand Pharmaceuticals Announces Launch of Pelthos Therapeutics to Accelerate Commercialization of ZELSUVMI™
JUPITER, Fla. & DURHAM, N.C., April 03, 2024--Ligand Pharmaceuticals (Nasdaq: LGND) today announced the launch of Pelthos Therapeutics (Pelthos), a biopharmaceutical company, and the appointment of seasoned industry executive Scott Plesha to the role of Chief Executive Officer.
